Takeda Halts Prostate Cancer Vaccine Development
This article was originally published in PharmAsia News
Takeda announced Oct. 17 that the company has decided to halt developing GVAX, a prostate cancer vaccine jointly developed with the U.S. biopharmaceutical company Cell Genesys. The decision is based on clinic trials conducted on 626 patients in Europe and the U.S., and the studies have not shown effective results in prolonging lives. Analysis shows the trial had less than a 30 percent chance of meeting its predefined primary endpoint of improvement in survival. Takada has been financing the development. (Click here for more - Japanese language
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.